Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
Sell
31
NVST Quote, Financials, Valuation and Earnings
Last price:
$18.27
Seasonality move
:
-1.87%
Day range:
$18.05 - $18.53
52-week range:
$14.22 - $23.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.26x
P/B ratio:
1.02x
Volume:
2.6M
Avg. volume:
2.8M
1-year change:
-3.23%
Market cap:
$3.1B
Revenue:
$2.5B
EPS (TTM):
-$6.53
Analysts' Opinion
-
Consensus RatingEnvista Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 9 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $19.04, Envista Holdings has an estimated upside of 4.22% from its current price of $18.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $18.27.
Fair Value
-
According to the consensus of 14 analysts, Envista Holdings has 4.22% upside to fair value with a price target of $19.04 per share.
NVST vs. S&P 500
-
Over the past 5 trading days, Envista Holdings has overperformed the S&P 500 by 6.3% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Envista Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Envista Holdings revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Envista Holdings reported revenues of $616.9M.
Earnings Growth
-
Envista Holdings earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Envista Holdings reported earnings per share of $0.10.
Enterprise value:
3.4B
EV / Invested capital:
0.77x
Price / LTM sales:
1.26x
EV / EBIT:
--
EV / Revenue:
1.37x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
12.81x
Price / Operating cash flow:
11.79x
Enterprise value / EBITDA:
27.56x
Gross Profit (TTM):
$1.4B
Return On Assets:
-19.85%
Net Income Margin (TTM):
-44.9%
Return On Equity:
-34.78%
Return On Invested Capital:
-24.02%
Operating Margin:
7.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.6B | $2.6B | $2.5B | $623.6M | $616.9M | |
| Gross Profit | $1.5B | $1.4B | $1.4B | $356.3M | $336M | |
| Operating Income | $323.8M | $296.1M | $136.5M | $53.3M | $47.4M | |
| EBITDA | $470.2M | $143.4M | -$896.8M | $87.6M | $74.6M | |
| Diluted EPS | $1.20 | -$0.72 | -$6.53 | $0.14 | $0.10 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.9B | $1.4B | $1.8B | $1.8B | |
| Total Assets | $6.3B | $6.6B | $6.6B | $6.6B | $5.5B | |
| Current Liabilities | $1.1B | $1.3B | $1.1B | $781.3M | $873.3M | |
| Total Liabilities | $2.6B | $2.5B | $2.3B | $2.4B | $2.4B | |
| Total Equity | $3.7B | $4B | $4.3B | $4.1B | $3B | |
| Total Debt | $1.3B | $1.4B | $1.4B | $1.5B | $1.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $182.3M | $312.9M | $296.5M | $40.3M | $300K | |
| Cash From Investing | -$684.4M | -$51.1M | -$52.7M | -$10.7M | -$8.8M | |
| Cash From Financing | $5.7M | $117.8M | -$118.7M | -$2.6M | -$17.6M | |
| Free Cash Flow | $108.9M | $261.2M | $267.8M | $29.3M | -$5.6M | |
NVST
Sector
Market Cap
$3.1B
$33.4M
Price % of 52-Week High
79.44%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-3.23%
-40%
Beta (5-Year)
0.975
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.66
200-day SMA
Sell
Level
$18.74
Bollinger Bands (100)
Sell
Level
16.23 - 20.33
Chaikin Money Flow
Sell
Level
-37.7M
20-day SMA
Buy
Level
$17.65
Relative Strength Index (RSI14)
Buy
Level
57.94
ADX Line
Buy
Level
25.31
Williams %R
Neutral
Level
-35.6401
50-day SMA
Buy
Level
$16.76
MACD (12, 26)
Buy
Level
0.37
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-154.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7303)
Sell
CA Score
(Annual)
Level (-0.6494)
Buy
Beneish M-Score
(Annual)
Level (-3.983)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (0.156)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Stock Forecast FAQ
In the current month, NVST has received 4 Buy ratings 9 Hold ratings, and 1 Sell ratings. The NVST average analyst price target in the past 3 months is $19.04.
-
Where Will Envista Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Envista Holdings share price will rise to $19.04 per share over the next 12 months.
-
What Do Analysts Say About Envista Holdings?
Analysts are divided on their view about Envista Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Envista Holdings is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Envista Holdings's Price Target?
The price target for Envista Holdings over the next 1-year time period is forecast to be $19.04 according to 14 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is NVST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Envista Holdings is a Hold. 9 of 14 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NVST?
You can purchase shares of Envista Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Envista Holdings shares.
-
What Is The Envista Holdings Share Price Today?
Envista Holdings was last trading at $18.27 per share. This represents the most recent stock quote for Envista Holdings. Yesterday, Envista Holdings closed at $18.27 per share.
-
How To Buy Envista Holdings Stock Online?
In order to purchase Envista Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
